FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
June 26, 2023 07:04 ET
|
FibroGen, Inc.
- Study did not meet the primary endpoint- Pamrevlumab was generally safe and well tolerated- ZEPHYRUS-2 Phase 3 study will be discontinued- Company to implement plan to extend cash runway into...
FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy
June 07, 2023 06:55 ET
|
FibroGen, Inc.
Study did not meet the primary endpointPamrevlumab was generally safe and well tolerated Topline results from LELANTOS-2 Phase 3 study of pamrevlumab in ambulatory patients with DMD expected 3Q 2023 ...
FibroGen to Present at Jefferies Global Healthcare Conference
June 06, 2023 16:01 ET
|
FibroGen, Inc.
SAN FRANCISCO, June 06, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following...
FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia
May 18, 2023 07:30 ET
|
FibroGen, Inc.
Met primary endpoint of noninferiority of roxadustat to erythropoietin alfaPlan to file supplemental New Drug Application in China SAN FRANCISCO and BEIJING, May 18, 2023 (GLOBE NEWSWIRE) --...
FibroGen Reports First Quarter 2023 Financial Results
May 08, 2023 16:01 ET
|
FibroGen, Inc.
• Topline Data From Four Phase 3 Trials Expected Through 3Q 2023 • Completed Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical Value • Entered Into...
FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics
May 08, 2023 16:00 ET
|
FibroGen, Inc.
FOR46, an ADC targeting CD46, is in Phase 1 development with potential applications in mCRPC and other CD46-expressing cancersCollaboration expands FibroGen’s clinical pipeline with potential...
FibroGen Announces Results for MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Myelodysplastic Syndromes (MDS)
May 05, 2023 07:30 ET
|
FibroGen, Inc.
SAN FRANCISCO, May 05, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that MATTERHORN, a Phase 3 clinical study of roxadustat for treatment of anemia in patients with...
FibroGen Announces Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical Value
May 01, 2023 07:00 ET
|
FibroGen, Inc.
Strengthens balance sheet with significant non-dilutive capital Aligned to support FibroGen operational plan Allows for the continued advancement of pamrevlumab, as well as our pre-clinical...
FibroGen to Report First Quarter 2023 Financial Results
April 24, 2023 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, April 24, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2023 financial results on Monday, May 8 after the market close. FibroGen will also...
FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-2, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis
April 03, 2023 07:00 ET
|
FibroGen, Inc.
- 372 IPF Patients Enrolled -- Topline Data Anticipated Mid-2024 - SAN FRANCISCO, April 03, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the completion of patient...